IH / iHuman Inc. - Depositary Receipt (Common Stock) - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

iHuman Inc. Announces First Quarter 2025 Unaudited Financial Results

Exhibit 99.1 iHuman Inc. Announces First Quarter 2025 Unaudited Financial Results BEIJING, China, Jun. 26, 2025 - iHuman Inc. (NYSE: IH) (“iHuman” or the “Company”), a leading provider of tech-powered, intellectual development products in China, today announced its unaudited financial results for the first quarter ended March 31, 2025. First Quarter 2025 Highlights · Revenues were RMB210.4 million

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 Commission File Number: 001-39591

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 Commission File Number: 001-39591 iHuman Inc. (Registrant’s Name) Building A, No. 1 Wangjing East Road, Chaoyang District, Beijing 100102 People’s Republic of China (Address of Princi

Our ref

Exhibit 15.1 Our ref JLH/773179-000001/32186162v1 iHuman Inc. Building A, No. 1 Wangjing East Road, Chaoyang District, Beijing 100102 People’s Republic of China 28 April 2025 Dear Sirs iHuman Inc. We have acted as legal advisers as to the laws of the Cayman Islands to iHuman Inc., an exempted company incorporated in the Cayman Islands with limited liability (the “Company”), in connection with the

IHUMAN INC. Amended and Restated Statement of PolicIES Governing Material non-public Information and The Prevention of InsideR Trading (AS ADOPTED BY THE BOARD OF DIRECTORS OF IHUMAN INC. ON December 1, 2023)

Exhibit 11.2 IHUMAN INC. Amended and Restated Statement of PolicIES Governing Material non-public Information and The Prevention of InsideR Trading (AS ADOPTED BY THE BOARD OF DIRECTORS OF IHUMAN INC. ON December 1, 2023) This Amended and Restated Statement of Policies Governing Material Non-Public Information and the Prevention of Insider Trading (this “Statement”) applies to all directors, offic

Certification by the Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Exhibit 13.1 Certification by the Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of iHuman Inc. (the “Company”) on Form 20-F for the year ended December 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Peng Dai, Chief Executive Officer of the Company, certify, pursuant to

Certification by the Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Exhibit 13.2 Certification by the Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of iHuman Inc. (the “Company”) on Form 20-F for the year ended December 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Vivien Weiwei Wang, Chief Financial Officer of the Company, certify, pu

Certification by the Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

Exhibit 12.1 Certification by the Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Peng Dai, certify that: 1.I have reviewed this annual report on Form 20-F of iHuman Inc.; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circu

Consent of Independent Registered Public Accounting Firm

Exhibit 15.3 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the Registration Statement (Form S-8 No. 333-254990) pertaining to the Share Incentive Plan of iHuman Inc. of our report dated April 28, 2025, with respect to the consolidated financial statements of iHuman Inc. included in this Annual Report (Form 20-F) for the year ended December

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE

Certification by the Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

Exhibit 12.2 Certification by the Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Vivien Weiwei Wang, certify that: 1.I have reviewed this annual report on Form 20-F of iHuman Inc.; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of

April 28, 2025

Exhibit 15.2 April 28, 2025 iHuman Inc. (the “Company”) Building A, No. 1 Wangjing East Road, Chaoyang District, Beijing 100102 People’s Republic of China Ladies and Gentlemen: We hereby consent to the use and reference to our name and our opinions and views under the captions “Item 3. Key Information—Permissions Required from the PRC Authorities for Our Operations,” “Item 3. Key Information—D. Ri

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission File Number: 001-3959

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission File Number: 001-39591 iHuman Inc. (Registrant’s Name) Building A, No. 1 Wangjing East Road, Chaoyang District, Beijing 100102 People’s Republic of China (Address of Princ

iHuman Inc. Announces Fourth Quarter and Fiscal Year 2024 Unaudited Financial Results

Exhibit 99.1 iHuman Inc. Announces Fourth Quarter and Fiscal Year 2024 Unaudited Financial Results BEIJING, China, Mar. 25, 2025 - iHuman Inc. (NYSE: IH) (“iHuman” or the “Company”), a leading provider of tech-powered, intellectual development products in China, today announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2024. Fourth Quarter 2024 Highl

iHuman Inc. Announces Third Quarter 2024 Unaudited Financial Results

Exhibit 99.1 iHuman Inc. Announces Third Quarter 2024 Unaudited Financial Results BEIJING, China, Dec. 26, 2024 - iHuman Inc. (NYSE: IH) (“iHuman” or the “Company”), a leading provider of tech-powered, intellectual development products in China, today announced its unaudited financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Highlights · Revenues were RMB239.4 mil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number: 001-39591 iHuman Inc. (Registrant’s Name) Building A, No. 1 Wangjing East Road, Chaoyang District, Beijing 100102 People’s Republic of China (Address of Pr

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission File Number: 001-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission File Number: 001-39591 iHuman Inc. (Registrant’s Name) Building A, No. 1 Wangjing East Road, Chaoyang District, Beijing 100102 People’s Republic of China (Address of P

iHuman Inc. Announces Second Quarter 2024 Unaudited Financial Results

Exhibit 99.1 iHuman Inc. Announces Second Quarter 2024 Unaudited Financial Results BEIJING, China, September 27, 2024 - iHuman Inc. (NYSE: IH) (“iHuman” or the “Company”), a leading provider of tech-powered, intellectual development products in China, today announced its unaudited financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Highlights · Revenues were RMB215.1

iHuman Inc. Announces First Quarter 2024 Unaudited Financial Results

Exhibit 99.1 iHuman Inc. Announces First Quarter 2024 Unaudited Financial Results BEIJING, China, June 28, 2024 - iHuman Inc. (NYSE: IH) (“iHuman” or the “Company”), a leading provider of tech-powered, intellectual development products in China, today announced its unaudited financial results for the first quarter ended March 31, 2024. First Quarter 2024 Highlights · Revenues were RMB235.0 million

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Commission File Number: 001-39591

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Commission File Number: 001-39591 iHuman Inc. (Registrant’s Name) Floor 8, Building B, No. 1 Wangjing East Road, Chaoyang District, Beijing 100102 People’s Republic of China (Address

Certification by the Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Exhibit 13.2 Certification by the Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of iHuman Inc. (the “Company”) on Form 20-F for the year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Vivien Weiwei Wang, Chief Financial Officer of the Company, certify, pu

Consent of Independent Registered Public Accounting Firm

Exhibit 15.3 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the Registration Statement (Form S-8 No. 333-254990) pertaining to the Share Incentive Plan of iHuman Inc. of our report dated April 25, 2024, with respect to the consolidated financial statements of iHuman Inc. included in this Annual Report (Form 20-F) for the year ended December

Our ref

Exhibit 15.1 Our refVSL/773179-000001/25925270v2 iHuman Inc. Floor 8, Building B, No. 1 Wangjing East Road Chaoyang District, Beijing 100102 People’s Republic of China April 25, 2024 Dear Sirs iHuman Inc. We have acted as legal advisers as to the laws of the Cayman Islands to iHuman Inc., an exempted company incorporated in the Cayman Islands with limited liability (the “Company”), in connection w

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE

IHUMAN INC. CLAWBACK POLICY

Exhibit 97.1 IHUMAN INC. CLAWBACK POLICY The Compensation Committee (the “Committee”) of the Board of Directors (the “Board”) of iHuman Inc. (the “Company”) believes that it is appropriate for the Company to adopt this Clawback Policy (the “Policy”) to be applied to the Executive Officers of the Company and adopts this Policy to be effective as of the Effective Date. 1. Definitions For purposes of

Certification by the Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

Exhibit 12.1 Certification by the Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Peng Dai, certify that: 1.I have reviewed this annual report on Form 20-F of iHuman Inc.; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circu

Certification by the Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

Exhibit 12.2 Certification by the Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Vivien Weiwei Wang, certify that: 1.I have reviewed this annual report on Form 20-F of iHuman Inc.; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of

April 25, 2024

Exhibit 15.2 April 25, 2024 iHuman Inc. (the “Company”) Floor 8, Building B, No. 1 Wangjing East Road Chaoyang District, Beijing 100102 Ladies and Gentlemen: We hereby consent to the use and reference to our name and our opinions and views under the captions “Item 3. Key Information—Permissions Required from the PRC Authorities for Our Operations,” “Item 3. Key Information—D. Risk Factors,” “Item

Tianjin Hongen Perfect Future Education Technology Co., Perfect Kunpeng (Beijing) Animation Co., Ltd. Perfect Kunpeng (Tianjin) Animation Technology Co., Ltd. Perfect Kunpeng (Beijing) Animation Technology Co., Ltd. Perfect Kunpeng (Chengdu) Animatio

Exhibit 4.11 Tianjin Hongen Perfect Future Education Technology Co., Ltd. Perfect Kunpeng (Beijing) Animation Co., Ltd. (Transferees) Perfect Kunpeng (Tianjin) Animation Technology Co., Ltd. Perfect Kunpeng (Beijing) Animation Technology Co., Ltd. Perfect Kunpeng (Chengdu) Animation Technology Co., Ltd. Perfect World Holding Group Co., Ltd. (Transferors) Assets Transfer Agreement February 2024 1 C

Certification by the Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Exhibit 13.1 Certification by the Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of iHuman Inc. (the “Company”) on Form 20-F for the year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Peng Dai, Chief Executive Officer of the Company, certify, pursuant to

iHuman Inc. Announces Fourth Quarter and Fiscal Year 2023 Unaudited Financial Results

Exhibit 99.1 iHuman Inc. Announces Fourth Quarter and Fiscal Year 2023 Unaudited Financial Results BEIJING, China, February 29, 2024 - iHuman Inc. (NYSE: IH) (“iHuman” or the “Company”), a leading provider of tech-powered, intellectual development products in China, today announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2023. Fourth Quarter 2023 H

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024 Commission File Number: 001-39591 iHuman Inc. (Registrant’s Name) Floor 8, Building B, No. 1 Wangjing East Road, Chaoyang District, Beijing 100102 People’s Republic of China (Addr

iHuman Inc. Announces Third Quarter 2023 Unaudited Financial Results

Exhibit 99.1 iHuman Inc. Announces Third Quarter 2023 Unaudited Financial Results BEIJING, China, December 28, 2023 - iHuman Inc. (NYSE: IH) (“iHuman” or the “Company”), a leading provider of tech-powered, intellectual development products in China, today announced its unaudited financial results for the third quarter ended September 30, 2023. Third Quarter 2023 Highlights ● Revenues were RMB261.5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File Number: 001-39591 iHuman Inc. (Registrant’s Name) Floor 8, Building B, No. 1 Wangjing East Road, Chaoyang District, Beijing 100102 People’s Republic of China (Addr

IHUMAN INC. Floor 8, Building B No. 1 Wangjing East Road Chaoyang District, Beijing 100102 People’s Republic of China

IHUMAN INC. Floor 8, Building B No. 1 Wangjing East Road Chaoyang District, Beijing 100102 People’s Republic of China December 1, 2023 VIA EDGAR Mr. Stephen Kim Mr. Robert Shapiro Ms. Cara Wirth Mr. Brian Fetterolf Division of Corporation Finance Office of Trade & Services Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 RE: iHuman Inc. (the “Company”) Form 20-F for Fis

IHUMAN INC. Floor 8, Building B No. 1 Wangjing East Road Chaoyang District, Beijing 100102 People’s Republic of China

IHUMAN INC. Floor 8, Building B No. 1 Wangjing East Road Chaoyang District, Beijing 100102 People’s Republic of China October 24, 2023 VIA EDGAR Mr. Dieter King Mr. Brian Fetterolf Division of Corporation Finance Office of Trade & Services Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 RE: iHuman Inc. (the “Company”) Form 20-F for Fiscal Year Ended December 31, 2022 R

ihuman INC. Floor 8, Building B No. 1 Wangjing East Road Chaoyang District, Beijing 100102 People’s Republic of China

ihuman INC. Floor 8, Building B No. 1 Wangjing East Road Chaoyang District, Beijing 100102 People’s Republic of China September 28, 2023 VIA EDGAR Mr. Dieter King Mr. Brian Fetterolf Division of Corporation Finance Office of Trade & Services Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 RE: iHuman Inc. (the “Company”) Form 20-F for Fiscal Year Ended December 31, 2022

iHuman Inc. Announces Second Quarter 2023 Unaudited Financial Results

Exhibit 99.1 iHuman Inc. Announces Second Quarter 2023 Unaudited Financial Results BEIJING, China, September 21, 2023 - iHuman Inc. (NYSE: IH) (“iHuman” or the “Company”), a leading provider of tech-powered, intellectual development products in China, today announced its unaudited financial results for the second quarter ended June 30, 2023. Second Quarter 2023 Highlights · Revenues were RMB241.0

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission File Number: 001-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission File Number: 001-39591 iHuman Inc. (Registrant’s Name) Floor 8, Building B, No. 1 Wangjing East Road, Chaoyang District, Beijing 100102 People’s Republic of China (Add

IHUMAN INC. Floor 8, Building B No. 1 Wangjing East Road Chaoyang District, Beijing 100102 People’s Republic of China

IHUMAN INC. Floor 8, Building B No. 1 Wangjing East Road Chaoyang District, Beijing 100102 People’s Republic of China August 31, 2023 VIA EDGAR Mr. Robert Shapiro Mr. Stephen Kim Mr. Christopher Dunham Mr. Kyle Wiley Mr. Dieter King Mr. Brian Fetterolf Division of Corporation Finance Office of Trade & Services Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 RE: iHuman

ihuman INC. Floor 8, Building B No. 1 Wangjing East Road Chaoyang District, Beijing 100102 People’s Republic of China

ihuman INC. Floor 8, Building B No. 1 Wangjing East Road Chaoyang District, Beijing 100102 People’s Republic of China August 11, 2023 VIA EDGAR Mr. Robert Shapiro Mr. Stephen Kim Mr. Christopher Dunham Mr. Kyle Wiley Mr. Dieter King Mr. Brian Fetterolf Division of Corporation Finance Office of Trade & Services Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 RE: iHuman

iHuman Inc. Announces First Quarter 2023 Unaudited Financial Results

Exhibit 99.1 iHuman Inc. Announces First Quarter 2023 Unaudited Financial Results BEIJING, China, June 21, 2023 - iHuman Inc. (NYSE: IH) (“iHuman” or the “Company”), a leading provider of tech-powered, intellectual development products in China, today announced its unaudited financial results for the first quarter ended March 31, 2023. First Quarter 2023 Highlights · Revenues reached a record-high

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2023 Commission File Number: 001-39591

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2023 Commission File Number: 001-39591 iHuman Inc. (Registrant’s Name) Floor 8, Building B, No. 1 Wangjing East Road, Chaoyang District, Beijing 100102 People’s Republic of China (Address

Certification by the Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

Exhibit 12.2 Certification by the Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Vivien Weiwei Wang, certify that: 1.I have reviewed this annual report on Form 20-F of iHuman Inc.; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of

April 25, 2023

Exhibit 15.2 April 25, 2023 iHuman Inc. (the “Company”) Floor 8, Building B, No. 1 Wangjing East Road Chaoyang District, Beijing 100102 Ladies and Gentlemen: We hereby consent to the use and reference to our name and our opinions and views under the captions “Item 3. Key Information—Permissions Required from the PRC Authorities for Our Operations,” “Item 3. Key Information—D. Risk Factors,” “Item

Our ref

Exhibit 15.1 Our refVSL/773179-000001/25925270v2 iHuman Inc. Floor 8, Building B, No. 1 Wangjing East Road Chaoyang District, Beijing 100102 People’s Republic of China April 25, 2023 Dear Sirs iHuman Inc. We have acted as legal advisers as to the laws of the Cayman Islands to iHuman Inc., an exempted company incorporated in the Cayman Islands with limited liability (the “Company”), in connection w

Certification by the Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

Exhibit 12.1 Certification by the Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Peng Dai, certify that: 1.I have reviewed this annual report on Form 20-F of iHuman Inc.; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE

Certification by the Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Exhibit 13.2 Certification by the Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of iHuman Inc. (the “Company”) on Form 20-F for the year ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Vivien Weiwei Wang, Chief Financial Officer of the Company, certify, pu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 Commission File Number: 001-3959

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 Commission File Number: 001-39591 iHuman Inc. (Registrant’s Name) Floor 8, Building B, No. 1 Wangjing East Road, Chaoyang District, Beijing 100102 People’s Republic of China (Address

Certification by the Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Exhibit 13.1 Certification by the Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of iHuman Inc. (the “Company”) on Form 20-F for the year ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Peng Dai, Chief Executive Officer of the Company, certify, pursuant to

Consent of Independent Registered Public Accounting Firm

Exhibit 15.3 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the Registration Statement (Form S-8 No. 333-254990) pertaining to the Share Incentive Plan of iHuman Inc. of our report dated April 25, 2023, with respect to the consolidated financial statements of iHuman Inc. included in this Annual Report (Form 20-F) for the year ended December

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number: 001-3959

6-K 1 tm2311136d16k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number: 001-39591 iHuman Inc. (Registrant’s Name) Floor 8, Building B, No. 1 Wangjing East Road, Chaoyang District, Beijing 100102 Pe

iHuman Inc. Announces Fourth Quarter and Fiscal Year 2022 Unaudited Financial Results

Exhibit 99.1 iHuman Inc. Announces Fourth Quarter and Fiscal Year 2022 Unaudited Financial Results BEIJING, China, March 31, 2023 - iHuman Inc. (NYSE: IH) (“iHuman” or the “Company”), a leading provider of tech-powered, intellectual development products in China, today announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2022. Fourth Quarter 2022 High

IH / iHuman Inc. American depositary shares, each representing five Class A ordinary shares / Arisaig Partners (Asia) Pte Ltd. Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

iHuman Inc. Announces Third Quarter 2022 Unaudited Financial Results

Exhibit 99.1 iHuman Inc. Announces Third Quarter 2022 Unaudited Financial Results BEIJING, China, December 8, 2022 - iHuman Inc. (NYSE: IH) (?iHuman? or the ?Company?), a leading provider of tech-powered, intellectual development products in China, today announced its unaudited financial results for the third quarter ended September 30, 2022. Third Quarter 2022 Highlights ? Revenues were RMB251.5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2022 Commission File Number: 001-3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2022 Commission File Number: 001-39591 iHuman Inc. (Registrant’s Name) Floor 8, Building 2, No. 1 Wangjing East Road, Chaoyang District, Beijing 100102 People’s Republic of China (Addr

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2022 Commission File Number: 001-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2022 Commission File Number: 001-39591 iHuman Inc. (Registrant’s Name) Floor 8, Building 2, No. 1 Wangjing East Road, Chaoyang District, Beijing 100102 People’s Republic of China (Add

iHuman Inc. Announces Second Quarter 2022 Unaudited Financial Results

Exhibit 99.1 iHuman Inc. Announces Second Quarter 2022 Unaudited Financial Results BEIJING, China, September 22, 2022 - iHuman Inc. (NYSE: IH) (?iHuman? or the ?Company?), a leading provider of tech-powered, intellectual development products in China, today announced its unaudited financial results for the second quarter ended June 30, 2022. Second Quarter 2022 Highlights ? Revenues were RMB230.6

iHuman Inc. Announces First Quarter 2022 Unaudited Financial Results

Exhibit 99.1 iHuman Inc. Announces First Quarter 2022 Unaudited Financial Results BEIJING, China, June 21, 2022 - iHuman Inc. (NYSE: IH) (?iHuman? or the ?Company?), a leading provider of tech-powered, intellectual development products in China, today announced its unaudited financial results for the first quarter ended March 31, 2022. First Quarter 2022 Highlights ? Revenues were RMB242.7 million

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2022 Commission File Number: 001-39591

6-K 1 tm2218964d16k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2022 Commission File Number: 001-39591 iHuman Inc. (Registrant’s Name) Floor 8, Building 2, No. 1 Wangjing East Road, Chaoyang District, Beijing 100102 Peo

CEO Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

Exhibit 12.1 Certification by the Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Peng Dai, certify that: 1. I have reviewed this annual report on Form 20-F of iHuman Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the cir

CEO Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Exhibit 13.1 Certification by the Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of iHuman Inc. (the “Company”) on Form 20-F for the fiscal year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Peng Dai, Chief Executive Officer of the Company, certify, pursu

Consent of Tian Yuan Law Firm

Exhibit 15.2 April 29, 2022 iHuman Inc. (the ?Company?) Floor 8, Building 2, No. 1 Wangjing East Road Chaoyang District, Beijing 100102 Ladies and Gentlemen: We hereby consent to the use and reference to our name and our opinions and views under the captions ?Item 3. Key Information?D. Risk Factors,? ?Item 4. Information on the Company?B. Business Overview?Regulations,? ?Item 4. Information on the

CFO Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

Exhibit 12.2 Certification by the Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Vivien Weiwei Wang, certify that: 1. I have reviewed this annual report on Form 20-F of iHuman Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light

CFO Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Exhibit 13.2 Certification by the Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of iHuman Inc. (the “Company”) on Form 20-F for the fiscal year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Vivien Weiwei Wang, Chief Financial Officer of the Company, cert

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F

Table of Contents ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.

Consent of Ernst & Young Hua Ming LLP, an independent registered public accounting firm

Exhibit 15.3 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the Registration Statement (Form S-8 No. 333-254990) pertaining to the Share Incentive Plan of iHuman Inc. of our report dated April 29, 2022, with respect to the consolidated financial statements of iHuman Inc. included in this Annual Report (Form 20-F) of iHuman Inc. for the year

Consent of Maples and Calder (Hong Kong) LLP

Exhibit 15.1 Our refVSL/773179-000001/22014469v1 iHuman Inc. Floor 8, Building 2, No. 1 Wangjing East Road Chaoyang District, Beijing 100102 People’s Republic of China 29 April 2022 Dear Sirs iHuman Inc. We have acted as legal advisers as to the laws of the Cayman Islands to iHuman Inc., an exempted company incorporated in the Cayman Islands with limited liability (the “Company”), in connection wi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2022 Commission File Number: 001-3959

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2022 Commission File Number: 001-39591 iHuman Inc. (Registrant?s Name) Floor 8, Building 2, No. 1 Wangjing East Road, Chaoyang District, Beijing 100102 People?s Republic of China (Address

iHuman Inc. Announces Fourth Quarter and Fiscal Year 2021 Unaudited Financial Results

Exhibit 99.1 iHuman Inc. Announces Fourth Quarter and Fiscal Year 2021 Unaudited Financial Results BEIJING, China, March 24, 2022 -iHuman Inc. (NYSE: IH) (?iHuman? or the ?Company?), a leading provider of tech-powered, intellectual development products in China, today announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2021. Fourth Quarter 2021 Highl

IH / iHuman Inc. American depositary shares, each representing five Class A ordinary shares / Arisaig Partners (Asia) Pte Ltd. Passive Investment

SC 13G/A 1 d941938613g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)*1 iHuman Inc. (Name of Issuer) Class A ordinary shares, par value US$0.0001 per share (Title of Class of Securities) 45175B109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the ap

IH / iHuman Inc. American depositary shares, each representing five Class A ordinary shares / Arisaig Partners (Asia) Pte Ltd. Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

iHuman Inc. Announces Third Quarter 2021 Unaudited Financial Results and Share Repurchase Program

Exhibit 99.1 iHuman Inc. Announces Third Quarter 2021 Unaudited Financial Results and Share Repurchase Program BEIJING, China, December 21, 2021 -iHuman Inc. (NYSE: IH) (?iHuman? or the ?Company?), a leading provider of tech-powered smart learning products in China, today announced its unaudited financial results for the third quarter ended September 30, 2021. The Company also announced that its b

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2021 Commission File Number: 001-3

6-K 1 tm2136009d16k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2021 Commission File Number: 001-39591 iHuman Inc. (Registrant’s Name) Floor 8, Building 2, No. 1 Wangjing East Road, Chaoyang District, Beijing 100102

iHuman Inc. Announces Second Quarter 2021 Unaudited Financial Results

Exhibit 99.1 iHuman Inc. Announces Second Quarter 2021 Unaudited Financial Results BEIJING, China, September 29, 2021 -iHuman Inc. (NYSE: IH) (?iHuman? or the ?Company?), a leading provider of tech-powered smart learning products in China, today announced its unaudited financial results for the second quarter ended June 30, 2021. Second Quarter 2021 Highlights ? Total revenues were RMB221.3 millio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2021 Commission File Number: 001-

6-K 1 tm2128780d16k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2021 Commission File Number: 001-39591 iHuman Inc. (Registrant’s Name) Floor 8, Building 2, No. 1 Wangjing East Road, Chaoyang District, Beijing 10010

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2021 Commission File Number: 001-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2021 Commission File Number: 001-39591 iHuman Inc. (Registrant?s Name) Floor 8, Building 2, No. 1 Wangjing East Road, Chaoyang District, Beijing 100102 People?s Republic of China (Add

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2021 Commission File Number: 001-39591

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2021 Commission File Number: 001-39591 iHuman Inc. (Registrant?s Name) Floor 8, Building 2, No. 1 Wangjing East Road, Chaoyang District, Beijing 100102 People?s Republic of China (Address

iHuman Inc. Announces First Quarter 2021 Unaudited Financial Results

Exhibit 99.1 iHuman Inc. Announces First Quarter 2021 Unaudited Financial Results BEIJING, China, June 8, 2021 -iHuman Inc. (NYSE: IH) (?Human? or the ?Company?), a leading childhood edutainment company in China, today announced its unaudited financial results for the first quarter ended March 31, 2021. First Quarter 2021 Highlights ? Total revenues were RMB226.7 million (US$34.6 million), a year-

CEO Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Exhibit 13.1 Certification by the Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of iHuman Inc. (the “Company”) on Form 20-F for the fiscal year ended December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Peng Dai, Chief Executive Officer of the Company, certify, pursu

Description of Securities

Exhibit 2.5 Description of Rights of Each Class of Securities Registered under Section 12 of the Securities Exchange Act of 1934 (the ?Exchange Act?) American Depositary Shares (?ADSs?), each representing five Class A ordinary shares of iHuman Inc. (?we,? ?our,? ?our company,? or ?us?) are listed on the New York Stock Exchange and the shares are registered under Section 12(b) of the Exchange Act.

Consent of Ernst & Young Hua Ming LLP, an independent registered public accounting firm

Exhibit 15.3 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the Registration Statement (Form S-8 No. 333-254990) pertaining to the Share Incentive Plan of iHuman Inc. of our report dated April 28, 2021, with respect to the consolidated financial statements of iHuman Inc. included in this Annual Report (Form 20-F) of iHuman Inc. for the year

CFO Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

Exhibit 12.2 Certification by the Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Vivien Weiwei Wang, certify that: 1. I have reviewed this annual report on Form 20-F of iHuman Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light

- 20-F

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020. OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)

CFO Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Exhibit 13.2 Certification by the Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report of iHuman Inc. (the ?Company?) on Form 20-F for the fiscal year ended December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the ?Report?), I, Vivien Weiwei Wang, Chief Financial Officer of the Company, cert

Consent of Maples and Calder (Hong Kong) LLP

Exhibit 15.1 Our ref VSL/773179-000001/19668379v2 iHuman Inc. Floor 8, Building 2, No. 1 Wangjing East Road Chaoyang District, Beijing 100102 People?s Republic of China 28 April 2021 Dear Sirs iHuman Inc. We have acted as legal advisers as to the laws of the Cayman Islands to iHuman Inc., an exempted company incorporated in the Cayman Islands with limited liability (the ?Company?), in connection w

CEO Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

Exhibit 12.1 Certification by the Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Peng Dai, certify that: 1. I have reviewed this annual report on Form 20-F of iHuman Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the cir

Consent of Tian Yuan Law Firm

Exhibit 15.2 April 28, 2021 iHuman Inc. (the ?Company?) Floor 8, Building 2, No. 1 Wangjing East Road Chaoyang District, Beijing 100102 Ladies and Gentlemen: We hereby consent to the use and reference to our name and our opinions and views under the captions ?Item 3. Key Information?D. Risk Factors,? ?Item 4. Information on the Company?B. Business Overview?Regulations,? ?Item 4. Information on the

Deposit Agreement among the Registrant, Deutsche Bank Trust Company Americas as the depositary and holders and beneficial owners of American Depositary Shares evidenced by American Depositary Receipts issued thereunder dated October 8, 2020 (incorporated herein by reference to Exhibit 4.3 to the registration statement on Form S-8 (File No. 333-254990), filed with the Securities and Exchange Commission on April 2, 2021)

Exhibit 4.3 Execution Version DEPOSIT AGREEMENT by and among IHUMAN INC. as Issuer, DEUTSCHE BANK TRUST COMPANY AMERICAS as Depositary, AND THE HOLDERS AND BENEFICIAL OWNERS OF AMERICAN DEPOSITARY SHARES EVIDENCED BY AMERICAN DEPOSITARY RECEIPTS ISSUED HEREUNDER Dated as of October 8, 2020 DEPOSIT AGREEMENT DEPOSIT AGREEMENT, dated as of October 8, 2020, by and among (i) iHuman Inc., a company inc

- S-8

As filed with the Securities and Exchange Commission on April 2, 2021 Registration No.

iHuman Inc. Announces Fourth Quarter and Fiscal Year 2020 Unaudited Financial Results

Exhibit 99.1 iHuman Inc. Announces Fourth Quarter and Fiscal Year 2020 Unaudited Financial Results BEIJING, China, March 25, 2021 ?iHuman Inc. (NYSE: IH) (?iHuman? or the ?Company?), a leading childhood edutainment company in China, today announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2020. Fourth Quarter 2020 Highlights ? Total revenues were RM

Current Report of Foreign Issuer - 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2021 Commission File Number: 001-39591 iHuman Inc. (Registrant?s Name) Floor 8, Building 2, No. 1 Wangjing East Road, Chaoyang District, Beijing 100102 People?s Republic of China (Address

JOINT FILING AGREEMENT

EXHIBIT 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with all other Reporting Persons (as such term is defined in the Schedule 13G referred to below) on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Class A or

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 Under the Securities Exchange Act of 1934 (Amendment No. )* iHuman Inc. (Name of Issuer) Class A ordinary shares, par value of $0.0001 per share (Title of Class

JOINT FILING AGREEMENT

EXHIBIT 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with all other Reporting Persons (as such term is defined in the Schedule 13G referred to below) on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Class A or

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102)

SC 13G 1 a21-55052sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 Under the Securities Exchange Act of 1934 (Amendment No. )* iHuman Inc. (Name of Issuer) Class A ordinary shares, par value o

JOINT FILING AGREEMENT

EXHIBIT 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with all other Reporting Persons (as such term is defined in the Schedule 13G referred to below) on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Class A or

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102)

SC 13G 1 a21-55051sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 Under the Securities Exchange Act of 1934 (Amendment No. )* iHuman Inc. (Name of Issuer) Class A ordinary shares, par value o

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)*

SC 13G 1 d866557713g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* iHuman Inc. (Name of Issuer) Class A ordinary shares, par value US$0.0001 per share (Title of Class of Securities) 45175B109 (CUSIP Number) October 12, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriat

iHuman Inc. Announces Third Quarter 2020 Unaudited Financial Results

Exhibit 99.1 iHuman Inc. Announces Third Quarter 2020 Unaudited Financial Results BEIJING, China, December 2, 2020 — iHuman Inc. (NYSE: IH) (“iHuman” or the “Company”), a leading childhood edutainment company in China, today announced its unaudited financial results for the third quarter ended September 30, 2020. Third Quarter 2020 Highlights · Total revenues were RMB156.9 million (US$23.1 million

Current Report of Foreign Issuer - 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2020 Commission File Number: 001-39591 iHuman Inc. (Registrant’s Name) K2, North America International Business Park, No. 108 Beiyuan Road, Chaoyang District, Beijing 100012 People’s R

7,000,000 American Depositary Shares iHuman Inc. Representing 35,000,000 Class A Ordinary Shares

Use these links to rapidly review the document TABLE OF CONTENTS INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Table of Contents Filed pursuant to Rule 424(b)(4) Registration No.

-

CORRESP 1 filename1.htm Credit Suisse Securities (USA) LLC Eleven Madison Avenue New York, New York 10010 United States of America Citigroup Global Markets Inc. 388 Greenwich Street New York, NY 10013 United States of America As representatives of the prospective underwriters VIA EDGAR October 6, 2020 Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington,

-

October 6, 2020 VIA EDGAR Ms. Mara Ransom Mr. Scott Anderegg Mr. Doug Jones Mr. Tony Watson Office of Trade & Services Division of Corporation Finance Office of Trade & Services U.S. Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Re: iHuman Inc. (CIK No. 0001814423) Registration Statement on Form F-1 (File No. 333-248647) Registration Statement on Form 8-A (File No. 001

Form of Underwriting Agreement

Exhibit 1.1 7,000,000 American Depositary Shares Representing 35,000,000 Class A Ordinary Shares, Par Value US$0.0001 Per Share IHUMAN INC. UNDERWRITING AGREEMENT , 2020 CREDIT SUISSE SECURITIES (USA) LLC, Eleven Madison Avenue, New York, N.Y. 10010-3629 United States of America CITIGROUP GLOBAL MARKETS INC. 388 Greenwich Street, New York, NY 10013, United States of America As Representatives of t

The description of the Registrant’s Class A ordinary shares incorporated by reference in the Registrant’s registration statement on Form 8-A (File No. 001-39591) filed with the Commission on October 5, 2020, including any amendment and report subsequently filed for the purpose of updating that description.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 iHuman Inc. (Exact name of registrant as specified in its charter) Cayman Islands Not Applicable (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)

-

SKADDEN, ARPS, SLATE, MEAGHER & FLOM 世達國際律師事務所 PARTNERS CHRISTOPHER W. BETTS GEOFFREY CHAN * SHU DU * ANDREW L. FOSTER * CHI T. STEVE KWOK * EDWARD H.P. LAM ¨* HAIPING LI * RORY MCALPINE ¨ JONATHAN B. STONE * PALOMA P. WANG ¨ (ALSO ADMITTED IN ENGLAND & WALES) * (ALSO ADMITTED IN NEW YORK) REGISTERED FOREIGN LAWYER Z. JULIE GAO (CALIFORNIA) 42/F, EDINBURGH TOWER, THE LANDMARK 15 QUEEN’S ROAD CENTR

- F-1/A

Use these links to rapidly review the document TABLE OF CONTENTS INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Table of Contents As filed with the Securities and Exchange Commission on October 5, 2020 Registration No.

- FORM F-6

As filed with the Securities and Exchange Commission on October 5, 2020 Registration No.

DEPOSIT AGREEMENT

DEPOSIT AGREEMENT by and among IHUMAN INC. as Issuer, DEUTSCHE BANK TRUST COMPANY AMERICAS as Depositary, AND THE HOLDERS AND BENEFICIAL OWNERS OF AMERICAN DEPOSITARY SHARES EVIDENCED BY AMERICAN DEPOSITARY RECEIPTS ISSUED HEREUNDER Dated as of , 2020 DEPOSIT AGREEMENT DEPOSIT AGREEMENT, dated as of , 2020, by and among (i) iHuman Inc., a company incorporated in the Cayman Islands, with its princi

Form of Deposit Agreement, among the Registrant, the depositary and the holders and beneficial owners of American Depositary Shares issued thereunder

Exhibit 4.3 DEPOSIT AGREEMENT by and among IHUMAN INC. as Issuer, DEUTSCHE BANK TRUST COMPANY AMERICAS as Depositary, AND THE HOLDERS AND BENEFICIAL OWNERS OF AMERICAN DEPOSITARY SHARES EVIDENCED BY AMERICAN DEPOSITARY RECEIPTS ISSUED HEREUNDER Dated as of October [•], 2020 DEPOSIT AGREEMENT DEPOSIT AGREEMENT, dated as of October [·], 2020, by and among (i) iHuman Inc., a company incorporated in t

-

SKADDEN, ARPS, SLATE, MEAGHER & FLOM PARTNERS CHRISTOPHER W. BETTS GEOFFREY CHAN * SHU DU * ANDREW L. FOSTER * CHI T. STEVE KWOK * EDWARD H.P. LAM ¨* HAIPING LI * RORY MCALPINE ¨ JONATHAN B. STONE * PALOMA P. WANG 世達國際律師事務所 42/F, EDINBURGH TOWER, THE LANDMARK 15 QUEEN’S ROAD CENTRAL, HONG KONG - TEL: (852) 3740-4700 FAX: (852) 3740-4727 www.skadden.com AFFILIATE OFFICES - BOSTON CHICAGO HOUSTON LO

Amended and Restated Memorandum and Articles of Association of the Registrant, effective immediately prior to the completion of this offering

Exhibit 3.2 THE COMPANIES LAW (2020 REVISION) OF THE CAYMAN ISLANDS COMPANY LIMITED BY SHARES AMENDED AND RESTATED MEMORANDUM OF ASSOCIATION OF IHUMAN INC. (adopted by a Special Resolution passed on September 22, 2020 and effective immediately prior to the completion of the initial public offering of the Company’s American Depositary Shares representing its Class A Ordinary Shares) 1. The name of

Registrant's Specimen Certificate for Class A Ordinary Shares

Exhibit 4.2 iHuman Inc. Number Class A Ordinary Shares Incorporated under the laws of the Cayman Islands Share capital is US$100,000 divided into 1,000,000,000 shares of a par value of US$0.0001 each, comprising (i) 700,000,000 Class A Ordinary Shares of a par value of US$0.0001 each, (ii) 200,000,000 Class B Ordinary Shares of a par value of US$0.0001 each, and (iii) 100,000,000 shares of a par v

- F-1/A

Use these links to rapidly review the document TABLE OF CONTENTS INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Table of Contents As filed with the Securities and Exchange Commission on September 24, 2020 Registration No.

Opinion of Tian Yuan Law Firm regarding certain PRC tax matters (included in Exhibit 99.2)

Exhibit 99.2 September 8, 2020 To: iHuman Inc. K2, North America International Business Park, No. 108 Beiyuan Road, Chaoyang District, Beijing 100012 People’s Republic of China Re: Legal Opinion Regarding Certain PRC Law Matters We are qualified lawyers of the People’s Republic of China (the “PRC”) and are qualified to issue an opinion on the laws and regulations of the PRC (for the purposes of th

English translation of executed form of the Spousal Consent Letter granted by the spouse of each individual shareholder of our VIE, as currently in effect

Exhibit 10.8 Letter of Consent I, Yu Jianhong (ID Card No: ***), am the lawful spouse of Hanfeng Chi (ID Card No: ***), and on this 24th day of June, 2020 hereby provide this Letter of Consent unconditionally and irrevocably as follows with respect to the equity of Tianjin Hongen Perfect Future Education Technology Co., Ltd. (the “Company”) held by Hanfeng Chi: I am informed that: (1) The entire e

-

SKADDEN, ARPS, SLATE, MEAGHER & FLOM PARTNERS CHRISTOPHER W. BETTS GEOFFREY CHAN * SHU DU * ANDREW L. FOSTER * CHI T. STEVE KWOK * EDWARD H.P. LAM ¨* HAIPING LI * RORY MCALPINE ¨ JONATHAN B. STONE * PALOMA P. WANG ¨ (ALSO ADMITTED IN ENGLAND & WALES) * (ALSO ADMITTED IN NEW YORK) REGISTERED FOREIGN LAWYER Z. JULIE GAO (CALIFORNIA) 世達國際律師事務所 42/F, EDINBURGH TOWER, THE LANDMARK 15 QUEEN’S ROAD CENTR

Share Incentive Plan

Exhibit 10.1 iHuman Inc. Share Incentive Plan ARTICLE 1 PURPOSE The purpose of the Plan is to promote the success and enhance the value of iHuman Inc., an exempted company incorporated under the laws of the Cayman Islands (the “Company”), by linking the personal interests of the Directors, Employees, and Consultants to those of the Company’s shareholders and by providing such individuals with an i

Powers of Attorney (included on signature page)

F-1 1 a2242270zf-1.htm F-1 Use these links to rapidly review the document TABLE OF CONTENTS INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Table of Contents As filed with the Securities and Exchange Commission on September 8, 2020 Registration No. 333- SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 iHuman Inc. (Exact name of R

Financial Support Letter by iHuman Inc. to our VIE

Exhibit 10.9 To: Tianjin Hongen Perfect Future Education Co., Ltd. To Whom It May Concern: To ensure the cash flow requirements of Tianjin Hongen Perfect Future Education Co., Ltd. (the “VIE”) operations are met and/or to set off any loss accrued during such operations, the undersigned, iHuman Inc. (the “Company”), is obligated and hereby undertakes to provide unlimited financial support to the VI

English translation of the Exclusive Call Option Agreement among Hongen Investment, our VIE and shareholders of our VIE dated March dated June 24, 2020

Exhibit 10.7 Exclusive Call Option Agreement This Exclusive Call Option Agreement (hereinafter referred to as the “Agreement”) was signed by the following parties on 24th day of June, 2020 in Beijing of the People’s Republic of China: Party A: Hongen Perfect Future (Tianjin) Investment Co., Ltd., a wholly foreign-owned enterprise legally established and subsisting under the laws of the PRC with a

Form of Employment Agreement between the Registrant and its executive officers

Exhibit 10.3 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”) is entered into as of , 2020 by and between iHuman Inc., an exempted company incorporated and existing under the laws of the Cayman Islands (the “Company”) and , an individual (Passport/ID Card No. ) (the “Executive”). RECITALS WHEREAS, the Company desires to employ the Executive and to assure itself of the services of t

English translation of the Equity Interest Pledge Agreement among Hongen Investment, our VIE and shareholders of our VIE dated June 24, 2020

Exhibit 10.5 Equity Pledge Agreement This Equity Pledge Agreement (hereinafter referred to as the “Agreement”) was signed by the following parties on this 24th day of June, 2020 in Beijing of the People’s Republic of China: Party A: Hongen Perfect Future (Tianjin) Investment Co., Ltd., a wholly foreign-owned enterprise legally established and subsisting under the laws of the PRC with a unified soc

Code of Business Conduct and Ethics of the Registrant

Exhibit 99.1 IHUMAN INC. CODE OF BUSINESS CONDUCT AND ETHICS I. PURPOSE This Code of Business Conduct and Ethics (the “Code”) contains general guidelines for conducting the business of iHuman Inc., a Cayman Islands company, and its subsidiaries and affiliates (collectively, the “Company”) consistent with the highest standards of business ethics, and is intended to qualify as a “code of ethics” wit

English translation of the investment agreement between Tianjin Share Xinghan and Shareholders of our VIE dated October 25, 2019 as supplemented by supplemental agreements dated November 16, 2019 and June 22, 2020

Exhibit 10.10 Investment Agreement Regarding Tianjin Hongen Perfect Future Education Technology Co., Ltd. This Investment Agreement (this “Investment Agreement”) was signed in Shenzhen, China, among the following parties on October 25, 2019 (the “Signing Date”): (1) Tianjin Hongen Perfect Future Education Technology Co., Ltd., a limited liability company registered and incorporated in Tianjin on M

English translation of the Exclusive Management Service and Business Cooperation Agreement between Hongen Investment and our VIE dated June 24, 2020

EX-10.6 9 a2242270zex-106.htm EX-10.6 Exhibit 10.6 Exclusive Management Services and Business Cooperation Agreement This Exclusive Management Services and Business Cooperation Agreement (hereinafter referred to as the “Agreement”) was signed by the following parties in Beijing of the People’s Republic of China on June 24, 2020. Party A: Hongen Perfect Future (Tianjin) Investment Co., Ltd., a wholl

Shareholders Agreement between the Registrant and other parties thereto dated June 8, 2020

Exhibit 4.4 SHAREHOLDERS AGREEMENT BY AND BETWEEN IHUMAN INC. ACADEMY MANAGEMENT LTD. HPF FUSION HOLDING LTD. PERSONS LISTED ON SCHEDULE I AND TIANJIN SHARE XINGHAN ENTERPRISE MANAGEMENT CONSULTING PARTNERSHIP (LIMITED PARTNERSHIP) Dated June 8, 2020 Table of Contents Page Article I DEFINITIONS Section 1.01 Definitions 1 Section 1.02 Interpretation 5 Article II CORPORATE GOVERNANCE Section 2.01 Ac

Form of Indemnification Agreement between the Registrant and its directors and executive officers

Exhibit 10.2 INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (this “Agreement”) is made as of , 2020 by and between iHuman Inc., an exempted company incorporated and existing under the laws of the Cayman Islands (the “Company”), and an individual, (Passport/PRC ID Card No. ) (the “Indemnitee”). WHEREAS, the Indemnitee has agreed to serve as a director or officer of the Company and in such

Memorandum and Articles of Association of the Registrant, as currently in effect

Exhibit 3.1 THE CAYMAN ISLANDS THE COMPANIES LAW (AS AMENDED) Memorandum of Association of iHuman Inc. THE CAYMAN ISLANDS THE COMPANIES LAW (AS AMENDED) MEMORANDUM OF ASSOCIATION OF iHuman Inc. (the “Company”) 1. Name The name of the Company is iHuman Inc. 2. Registered Office The registered office of the Company shall be situated at the Office of Sertus Incorporations (Cayman) Limited, Sertus Cha

Consent of Frost & Sullivan

Exhibit 99.3 [Frost & Sullivan Letterhead] September 8, 2020 iHuman Inc. K2, North America International Business Park, No. 108 Beiyuan Road Chaoyang District, Beijing 100012 People’s Republic of China Re: Consent of Frost & Sullivan Ladies and Gentlemen, We understand that iHuman Inc. (the “Company”) plans to file a registration statement on Form F-1 (the “Registration Statement”) with the United

Principle Subsidiaries of the Registrant

Exhibit 21.1 Significant Subsidiaries of the Registrant Subsidiary Place of Incorporation iHuman Online Limited Hong Kong Hongen Perfect Future (Tianjin) Investment Co., Ltd. PRC Consolidated Variable Interest Entity Place of Incorporation Tianjin Hongen Perfect Future Education Technology Co., Ltd. PRC Subsidiary of Consolidated Variable Interest Entity Place of Incorporation Beijing Hongen Perfe

English translation of the executed form of the Powers of Attorney granted by shareholders of our VIE, as currently in effect, and a schedule of all executed Powers of Attorney adopting the same form

Exhibit 10.4 Power of Attorney I, [Name of Shareholder], with identity card number of [Number], am a Chinese citizen, with domicile at [Address], and as of the date of signing this Power of Attorney hold [Percentage]% equity of Tianjin Hongen Perfect Future Education Technology Co., Ltd. (hereinafter referred to as the “Company”). In respect of the aforesaid equity, I hereby irrevocably authorize

Investment Agreement Regarding Tianjin Hongen Perfect Future Education Technology Co., Ltd.

Exhibit 10.10 Investment Agreement Regarding Tianjin Hongen Perfect Future Education Technology Co., Ltd. This Investment Agreement (this “Investment Agreement”) was signed in Shenzhen, China, among the following parties on October 25, 2019 (the “Signing Date”): (1) Tianjin Hongen Perfect Future Education Technology Co., Ltd., a limited liability company registered and incorporated in Tianjin on M

Exclusive Management Services and Business Cooperation Agreement

Exhibit 10.6 Exclusive Management Services and Business Cooperation Agreement This Exclusive Management Services and Business Cooperation Agreement (hereinafter referred to as the “Agreement”) was signed by the following parties in Beijing of the People’s Republic of China on June 24, 2020. Party A: Hongen Perfect Future (Tianjin) Investment Co., Ltd., a wholly foreign-owned enterprise legally est

Power of Attorney

Exhibit 10.4 Power of Attorney I, [Name of Shareholder], with identity card number of [Number], am a Chinese citizen, with domicile at [Address], and as of the date of signing this Power of Attorney hold [Percentage]% equity of Tianjin Hongen Perfect Future Education Technology Co., Ltd. (hereinafter referred to as the ?Company?). In respect of the aforesaid equity, I hereby irrevocably authorize

Letter of Consent

Exhibit 10.8 Letter of Consent I, Yu Jianhong (ID Card No: ***), am the lawful spouse of Hanfeng Chi (ID Card No: ***), and on this 24th day of June, 2020 hereby provide this Letter of Consent unconditionally and irrevocably as follows with respect to the equity of Tianjin Hongen Perfect Future Education Technology Co., Ltd. (the “Company”) held by Hanfeng Chi: I am informed that: (1) The entire e

-

SKADDEN, ARPS, SLATE, MEAGHER & FLOM PARTNERS 世達國際律師事務所 AFFILIATE OFFICES CHRISTOPHER W.

Equity Pledge Agreement

Exhibit 10.5 Equity Pledge Agreement This Equity Pledge Agreement (hereinafter referred to as the ?Agreement?) was signed by the following parties on this 24th day of June, 2020 in Beijing of the People?s Republic of China: Party A: Hongen Perfect Future (Tianjin) Investment Co., Ltd., a wholly foreign-owned enterprise legally established and subsisting under the laws of the PRC with a unified soc

-

Use these links to rapidly review the document TABLE OF CONTENTS INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Table of Contents As confidentially submitted to the Securities and Exchange Commission on August 13, 2020 Registration No.

To: Tianjin Hongen Perfect Future Education Co., Ltd.

Exhibit 10.9 To: Tianjin Hongen Perfect Future Education Co., Ltd. To Whom It May Concern: To ensure the cash flow requirements of Tianjin Hongen Perfect Future Education Co., Ltd. (the “VIE”) operations are met and/or to set off any loss accrued during such operations, the undersigned, iHuman Inc. (the “Company”), is obligated and hereby undertakes to provide unlimited financial support to the VI

Exclusive Call Option Agreement

Exhibit 10.7 Exclusive Call Option Agreement This Exclusive Call Option Agreement (hereinafter referred to as the “Agreement”) was signed by the following parties on 24th day of June, 2020 in Beijing of the People’s Republic of China: Party A: Hongen Perfect Future (Tianjin) Investment Co., Ltd., a wholly foreign-owned enterprise legally established and subsisting under the laws of the PRC with a

SHAREHOLDERS AGREEMENT BY AND BETWEEN IHUMAN INC. ACADEMY MANAGEMENT LTD. HPF FUSION HOLDING LTD. PERSONS LISTED ON SCHEDULE I TIANJIN SHARE XINGHAN ENTERPRISE MANAGEMENT CONSULTING PARTNERSHIP (LIMITED PARTNERSHIP) Dated June 8, 2020

Exhibit 4.4 SHAREHOLDERS AGREEMENT BY AND BETWEEN IHUMAN INC. ACADEMY MANAGEMENT LTD. HPF FUSION HOLDING LTD. PERSONS LISTED ON SCHEDULE I AND TIANJIN SHARE XINGHAN ENTERPRISE MANAGEMENT CONSULTING PARTNERSHIP (LIMITED PARTNERSHIP) Dated June 8, 2020 Table of Contents Page Article I DEFINITIONS Section 1.01 Definitions 1 Section 1.02 Interpretation 5 Article II CORPORATE GOVERNANCE Section 2.01 Ac

-

DRSLTR 1 filename1.htm SKADDEN, ARPS, SLATE, MEAGHER & FLOM 世達國際律師事務所 PARTNERS 42/F, EDINBURGH TOWER, THE LANDMARK AFFILIATE OFFICES CHRISTOPHER W. BETTS 15 QUEEN’S ROAD CENTRAL, HONG KONG GEOFFREY CHAN * BOSTON SHU DU * TEL: (852) 3740-4700 CHICAGO ANDREW L. FOSTER * FAX: (852) 3740-4727 HOUSTON CHI T. STEVE KWOK * www.skadden.com LOS ANGELES EDWARD H.P. LAM ¨* NEW YORK HAIPING LI * PALO ALTO ROR

-

Use these links to rapidly review the document TABLE OF CONTENTS INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Table of Contents As confidentially submitted to the Securities and Exchange Commission on June 26, 2020 Registration No.